Product Development

CMC Outsourcing Support

Helping you navigate complex discovery, selection, and management needs

Our subject matter experts guide you in all phases of finding, engaging, and managing a CDMO. We create tailored evaluation criteria designed around your day-to-day needs as well as your short- and long-term business goals. Our services will:
  • Identify, evaluate, and select CDMOs based on fit for project and client
  • Review and help negotiate master services agreements
  • Manage CDMOs and advocate on behalf of client to achieve desired outcome and deliverables

We also support and oversee the following processes:

  • Cell line, process, and formulation development
  • Development and validation of analytical methods for in-process, release, and stability
  • Design specifications for release of bulk drug substance and products
  • Clinical filling of drug products
  • Clinical packaging, labeling, and distribution
  • Process validation
  • Commercial manufacturing

Why choose Alira Health?

As our client, you can rely on Alira Health’s dedicated, knowledgeable team to lead and support your outsourcing activities. You’ll benefit from our:

  • Extensive industry outsourcing expertise in the identification, evaluation, and selection of CDMOs, and managing the relationship with CDMOs to ensure that the client’s needs are met
  • Strong technical management at all stages from preclinical process development through manufacturing
  • Commitment to client advocacy with vendors that drives holistic solutions tailored to your business needs and goals
  • Full spectrum development support from product decision through clinical trials, process validation, and commercial manufacturing
  • Packaging, labeling, and shipping support and management

Related news

Research & Development
Publications June 9, 2021
EU Supply Integrity Guidelines
Check out Alira Health's latest publication, “EU Supply Integrity Guidelines”. In the document, best practices for European distribution and supply integrity management are highlighted(...)
Research & Development
Publications May 27, 2021
Buffers – Navigating New Demands On Downstream Raw Materials
The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing(...)
Research & Development
Publications April 26, 2021
Recombinant Human Polyclonal Antibodies to Treat Disease
Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their(...)
Research & Development
News March 15, 2021
Alira Health Welcomes Nikole Siegmund, Vice President, Preclinical
BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Nikole Siegmund has joined the firm(...)
Research & Development
Publications March 9, 2021
A Primer on Potency Assays for Release of Biologics
A key criterion in determining the quality of a biologic product is whether it has maintained its biological activity or “potency.”
Advanced Analytics Regulatory Research & Development
News November 20, 2020
Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round
Alira Health congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device toward clinical trials.(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.